Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer

Eric D. Bernstein, Scott M. Herbert, Nasser Hanna

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Surgical resection remains the cornerstone of therapy for early-stage disease and offers the best chance for cure. Local and distant failure rates, however, remain unacceptably high with surgery alone. Radiation and systemic chemotherapy have been used to reduce recurrences in early-stage disease. Neoadjuvant and adjuvant strategies both offer sound theoretical benefit, but evidence supporting this has been lacking. The publication of a meta-analysis in 1995 triggered a reevaluation of adjuvant chemotherapy. Four randomized trials reported in the last 2 years support the use of adjuvant platinum-based chemotherapy. Methods: This article reviews the history of clinical trials evaluating neoadjuvant and adjuvant therapy in non-small-cell lung cancer. Results: Adjuvant chemotherapy improves 5-year survival rates by approximately 5%-15% compared with surgery alone. Conclusions: Surgical resection followed by adjuvant chemotherapy is the standard of care treatment for patients with completely resected stage I, II, and IIIA non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)291-301
Number of pages11
JournalAnnals of Surgical Oncology
Volume13
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Radiotherapy
Drug Therapy
Neoadjuvant Therapy
Standard of Care
Platinum
Publications
Meta-Analysis
Therapeutics
Survival Rate
History
Clinical Trials
Radiation
Recurrence

Keywords

  • Adjuvant chemotherapy
  • Lung neoplasms
  • Non-small-cell lung carcinoma
  • Radiotherapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer. / Bernstein, Eric D.; Herbert, Scott M.; Hanna, Nasser.

In: Annals of Surgical Oncology, Vol. 13, No. 3, 03.2006, p. 291-301.

Research output: Contribution to journalArticle

@article{bece538ba95b4ad799d2bc8997fd202c,
title = "Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer",
abstract = "Background: Surgical resection remains the cornerstone of therapy for early-stage disease and offers the best chance for cure. Local and distant failure rates, however, remain unacceptably high with surgery alone. Radiation and systemic chemotherapy have been used to reduce recurrences in early-stage disease. Neoadjuvant and adjuvant strategies both offer sound theoretical benefit, but evidence supporting this has been lacking. The publication of a meta-analysis in 1995 triggered a reevaluation of adjuvant chemotherapy. Four randomized trials reported in the last 2 years support the use of adjuvant platinum-based chemotherapy. Methods: This article reviews the history of clinical trials evaluating neoadjuvant and adjuvant therapy in non-small-cell lung cancer. Results: Adjuvant chemotherapy improves 5-year survival rates by approximately 5{\%}-15{\%} compared with surgery alone. Conclusions: Surgical resection followed by adjuvant chemotherapy is the standard of care treatment for patients with completely resected stage I, II, and IIIA non-small-cell lung cancer.",
keywords = "Adjuvant chemotherapy, Lung neoplasms, Non-small-cell lung carcinoma, Radiotherapy",
author = "Bernstein, {Eric D.} and Herbert, {Scott M.} and Nasser Hanna",
year = "2006",
month = "3",
doi = "10.1245/ASO.2006.01.015",
language = "English",
volume = "13",
pages = "291--301",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer

AU - Bernstein, Eric D.

AU - Herbert, Scott M.

AU - Hanna, Nasser

PY - 2006/3

Y1 - 2006/3

N2 - Background: Surgical resection remains the cornerstone of therapy for early-stage disease and offers the best chance for cure. Local and distant failure rates, however, remain unacceptably high with surgery alone. Radiation and systemic chemotherapy have been used to reduce recurrences in early-stage disease. Neoadjuvant and adjuvant strategies both offer sound theoretical benefit, but evidence supporting this has been lacking. The publication of a meta-analysis in 1995 triggered a reevaluation of adjuvant chemotherapy. Four randomized trials reported in the last 2 years support the use of adjuvant platinum-based chemotherapy. Methods: This article reviews the history of clinical trials evaluating neoadjuvant and adjuvant therapy in non-small-cell lung cancer. Results: Adjuvant chemotherapy improves 5-year survival rates by approximately 5%-15% compared with surgery alone. Conclusions: Surgical resection followed by adjuvant chemotherapy is the standard of care treatment for patients with completely resected stage I, II, and IIIA non-small-cell lung cancer.

AB - Background: Surgical resection remains the cornerstone of therapy for early-stage disease and offers the best chance for cure. Local and distant failure rates, however, remain unacceptably high with surgery alone. Radiation and systemic chemotherapy have been used to reduce recurrences in early-stage disease. Neoadjuvant and adjuvant strategies both offer sound theoretical benefit, but evidence supporting this has been lacking. The publication of a meta-analysis in 1995 triggered a reevaluation of adjuvant chemotherapy. Four randomized trials reported in the last 2 years support the use of adjuvant platinum-based chemotherapy. Methods: This article reviews the history of clinical trials evaluating neoadjuvant and adjuvant therapy in non-small-cell lung cancer. Results: Adjuvant chemotherapy improves 5-year survival rates by approximately 5%-15% compared with surgery alone. Conclusions: Surgical resection followed by adjuvant chemotherapy is the standard of care treatment for patients with completely resected stage I, II, and IIIA non-small-cell lung cancer.

KW - Adjuvant chemotherapy

KW - Lung neoplasms

KW - Non-small-cell lung carcinoma

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=32844462559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844462559&partnerID=8YFLogxK

U2 - 10.1245/ASO.2006.01.015

DO - 10.1245/ASO.2006.01.015

M3 - Article

C2 - 16450219

AN - SCOPUS:32844462559

VL - 13

SP - 291

EP - 301

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 3

ER -